Table 2

Patient characteristics of durable responders (PFS >24 months) and non-durable responders (PFS <24 months)

Clinical characteristicsDurable responders: PFS >24 months (N=150)Non-durable responders: PFS <24 months (N=1040)P value
Age at diagnosis69.0 (59.0; 75.0)68.0 (61.0; 75.0)0.714
Practice type0.703
 Academic13 (8.67%)77 (7.40%)
 Community137 (91.3%)963 (92.6%)
Gender0.791
 Female75 (50.0%)504 (48.5%)
 Male75 (50.0%)536 (51.5%)
Self-reported race0.250
 White108 (72.0%)717 (68.9%)
 Black or African American15 (10.0%)83 (7.98%)
 Missing10 (6.67%)74 (7.12%)
 Other race17 (11.33%)166 (16.0%)
Histology0.012
 Non-squamous cell carcinoma124 (82.7%)748 (71.9%)
 NSCLC histology NOS7 (4.67%)50 (4.81%)
 Squamous cell carcinoma19 (12.7%)242 (23.3%)
Stage0.728
 I15 (10.0%)84 (8.08%)
 II10 (6.67%)89 (8.56%)
 III22 (14.7%)171 (16.4%)
 IV100 (66.7%)682 (65.6%)
 Unknown3 (2.00%)14 (1.35%)
History of smoking0.427
 History of smoking137 (91.3%)972 (93.5%)
 No history of smoking13 (8.67%)68 (6.54%)
PD-L1 (TS)<0.001
 <1%31 (20.7%)365 (35.1%)
 1–49%33 (22.0%)308 (29.6%)
 ≥50%86 (57.3%)367 (35.3%)
TMB<0.001
 <1068 (45.3%)660 (63.5%)
 10~2044 (29.3%)292 (28.1%)
 ≥2038 (25.3%)88 (8.46%)
Therapy class0.187
 ICPI67 (44.7%)402 (38.7%)
 ChemoICPI83 (55.3%)638 (61.3%)
  • chemoICPI, ICPI with chemotherapy; ICPI, immune checkpoint inhibitors ; NOS, not otherwise specified; NSCLC, non-small cell lung cancer ; PD-L1, programmed death ligand-1; PFS, progression-free survival ; TMB, tumor mutational burden ; TS, tumor staining.